Previous 10 | Next 10 |
Dr. Hayslip to lead development programs for avutometinib, including Verastem Oncology’s international confirmatory Phase 3 RAMP 301 clinical trial, and advance pipeline assets Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for ...
2024-03-28 15:00:00 ET More on the markets Where This Market Is Going (Technical Analysis) SPY: 2 Opposing Forces Wall Street Lunch: Fed Not Spooked By Recent Inflation Overbought conditions flash across all market caps: Bespoke Investment Group Energ...
2024-03-24 08:01:00 ET Westport Fuel Systems ( WPRT ) is set to report its Q4 earnings on Monday after the closing bell. The stock, which has dropped about 24% over a 12-month period, has received a Buy rating from Wall Street analysts, while Seeking Alpha's Quant Rating system has ...
Findings presented at SGO 2024 show 87% of respondents afraid of making long-term plans due to the possibility of a shorter life expectancy 84% say dealing with treatment side effects has negatively impacted their emotional well-being, and 94% worry about LGSOC returning despite treatment...
2024-03-14 17:16:51 ET More on Verastem Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy Verastem gets FDA fast track status for lung cancer drug combo Seek...
Initiated confirmatory Phase 3 RAMP 301 trial evaluating avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer; on track to submit rolling NDA for accelerated approval in H1 2024; preparations underway for potential commercial launch in 2025 Granted FDA Fast...
Late-breaking oral presentation of a subgroup analysis in RAMP 201 Part A heavily pretreated patients receiving avutometinib and defactinib and their best response compared to most recent prior therapy Plenary oral presentation of preclinical efficacy of the combination of avutometinib an...
2024-03-11 05:50:46 ET More on related stocks: Oracle Q3 Earnings Preview: Cloud Computing Business In Focus Blink Charging: EV Tailwinds Offer A Path To Profitability In 2025 Ulta Beauty: We Are Not Adding To Our Position Before The Earnings Release (Rating Downgrad...
2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...
2024-03-06 05:48:01 ET Read the full article on Seeking Alpha For further details see: Verastem gets FDA orphan drug status for low-grade ovarian cancer therapy
News, Short Squeeze, Breakout and More Instantly...
2024-05-18 20:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Plan to announce topline RAMP 201 data with the start of planned rolling NDA submission for avutometinib and defactinib combination in recurrent low-grade serous ovarian cancer in Q2 2024 FDA Fast Track Designation granted for avutometinib in combination with adagrasib for the treatment o...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that its management team will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 20...